Response to Hydroxyurea in a Patient With Sickle Cell Hepatopathy: A Case Report.
| Autor: | Safhi MA; Medicine, King Abdulaziz University Faculty of Medicine, Jeddah, SAU., Baghdadi RM; Internal Medicine, King Abdulaziz University Faculty of Medicine, Jeddah, SAU., Al-Marzouki AF; Hematology, King Abdulaziz University Faculty of Medicine, Jeddah, SAU., Al-Sayes F; Hematology, King Abdulaziz University Faculty of Medicine, Jeddah, SAU. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2021 Dec 23; Vol. 13 (12), pp. e20649. Date of Electronic Publication: 2021 Dec 23 (Print Publication: 2021). |
| DOI: | 10.7759/cureus.20649 |
| Abstrakt: | Sickle cell hepatopathy is an underreported entity lacking clear management guidelines. This case highlights the potential role of hydroxyurea (HU) in improving the hepatic dysfunction seen among patients with sickle cell disease (SCD). We herein present the clinical course of a patient prior to and after the initiation of hydroxyurea with an emphasis on long-term outcomes and the patterns of liver injury over a 15-year time course. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Safhi et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|